Skip to main content
SpringerLink
Log in

The Role of Atypical Antipsychotics in the Treatment of Movement Disorders

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

An atypical antipsychotic drug is loosely defined by its ability to produce an antipsychotic effect without inducing extrapyramidal symptoms (EPS). To date, 4 atypical antipsychotics have been released in the US: clozapine, quetiapine, olanzapine and risperidone, which are listed in decreasing order of ‘atypicality’ based on clinical and preclinical studies. While we await the outcome of trials with quetiapine on parkinsonian patients (considered the most stringent test of the atypicality of a drug), clozapine remains the prototypic atypical antipsychotic drug. Disappointing reports of risperidone-induced parkinsonism raise questions about the atypical nature of this drug. Olanzapine appears to be intermediate between risperidone and clozapine in inducing EPS.

Drug-induced psychosis in Parkinson’s disease and antipsychotic-induced movement disorders in psychotic patients are the most common indications for an atypical antipsychotic in patients with movement disorders. In drug-induced psychosis in Parkinson’s disease, the antiparkinsonians are first reduced until psychosis resolves. Unfortunately, motor function is often compromised as a result. The addition of an atypical antipsychotic drug, without altering the regimen of antiparkinsonians, often controls psychosiswithout compromising motor function. Depending on the atypical antipsychotic used, the dosage required may be substantially lower than that for schizophrenic patients.

No treatment strategy has been proven to be clearly superior in suppressing antipsychotic-induced movement disorders such as tardive dyskinesia, tardive akathisia and dystonia. Nonetheless, a review of the available data strongly suggests that clozapine has substantially less risk of inducing tardive dyskinesia as compared with conventional antipsychotic agents. No case of tardive dyskinesia developing in patients who have taken clozapine as their only antipsychotic has yet been reported. Although there is evidence that clozapine may have an active therapeutic effect against pre-existing tardive dyskinesia, this remains inconclusive.

Data on the use of clozapine for tremor in Parkinson’s disease suggest significant benefit. Clozapine has also been reported to be useful in a variety of movement disorders including levodopa-induced dyskinesia, nocturnal akathisia and dystonia in Parkinson’s disease, but the number of patients involved is small. No definitive conclusion on the role of atypical antipsychotic agents in other behavioural disorders such as depression, anxiety and sleep fragmentation in Parkinson’s disease, as well as in other movement disorders, can be made until well planned long term double-blind trials have been performed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of D1, D2 and serotonin 2 pK1 values. J Pharmacol Exp Ther 1989; 251: 238–46

    PubMed  CAS  Google Scholar 

  2. Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1277–86

    Google Scholar 

  3. Arnt J, Skarsfeld T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropharmacology 1998; 18: 63–101

    CAS  Google Scholar 

  4. Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective compound. Drug Dev Res 1991; 22: 239–50

    CAS  Google Scholar 

  5. Schotte A, Janssen PFM, Gommeren W. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57–73

    PubMed  CAS  Google Scholar 

  6. Van Tol HHM, Buzow JR, Guan H, et al. Cloning of the gene for human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–14

    PubMed  Google Scholar 

  7. Leysen JE, Janssen PMF, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmaol (Berl) 1993; 112 (1 Suppl. ): 40–54

    Google Scholar 

  8. Moore NA, Calligaro DO, Wong TD, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2: 281–93

    Google Scholar 

  9. Saller CF, Salama AL. Seroquel: biochemical profile of a potentialatypical antipsychotic. Psychopharmacol (Berl) 1993; 112: 285–92

    CAS  Google Scholar 

  10. Creese A, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481–3

    PubMed  CAS  Google Scholar 

  11. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–9

    PubMed  CAS  Google Scholar 

  12. Richelson E. Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984; 103: 197–204

    PubMed  CAS  Google Scholar 

  13. Miller RJ, Hiley CR. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 1974; 248: 596–87

    PubMed  CAS  Google Scholar 

  14. Snyder S, Greenberg D, Yamamura HI. Antischizophreni drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974; 31: 51–61

    Google Scholar 

  15. Tamminga CA, Lahti AC. The new generation of antipsychotic drugs. Int Clin Psychopharmacol 1996; 11 Suppl. 2: 73–6

    Google Scholar 

  16. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995; 16: 270–5

    PubMed  CAS  Google Scholar 

  17. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746–54

    PubMed  CAS  Google Scholar 

  18. Wolters ECH, Hurwitz TA, Peppard RF, et al. Clozapine: an antipsychotic agent for Parkinson’s disease? Clin Neuropharmacol 1989; 12: 83–90

    PubMed  CAS  Google Scholar 

  19. Physicians Desk Reference, 52nd ed. Montvale, NJ: Medical Economics Data Productions Co, 1998: 1309, 1512, 1834, 1997

  20. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 Suppl. 10: 55–62

    PubMed  CAS  Google Scholar 

  21. Regis E. Precis de Psychiatrie. Paris: Gaston Doiz, 1906

    Google Scholar 

  22. Jacson JA, Free GBM, Pike HV. The psychiatric manifestations in paralysis agitans. Arch Neurol Psychiatry 1923; 10: 680–4

    Google Scholar 

  23. Friedman JH. The management of levodopa psychoses. Clin Neuropharmacol 1991; 14: 283–95

    PubMed  CAS  Google Scholar 

  24. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurol 1993; 60: 703–6

    PubMed  CAS  Google Scholar 

  25. Melamed E, Achiron A, Shapira A, et al. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 1991; 14: 273–8

    PubMed  CAS  Google Scholar 

  26. Klawans HL. Levodopa-induced psychosis. Psychiatr Ann 1978; 8: 447–51

    Google Scholar 

  27. Fischer P, Danielczyk W, Simanyi M, et al. Dopaminergic psychosis in advanced Parkinson’s disease. In: Streifler MB, Korczyn AD, Melamed E, et al., editors. Advances in neurology. Vol 53. Parkinson’s disease: anatomy, pathology and therapy. New York: Raven Press, 1990: 391–7

    Google Scholar 

  28. Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc 1991; 33: 708–16

    Google Scholar 

  29. Nausieda PA, Weiner WJ, Kaplan LR, et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol 1982; 5: 183–94

    PubMed  CAS  Google Scholar 

  30. Sacks OW, Kohl MS, Messeloff CR, et al. Effects of levodopa in parkinsonian patients with dementia. Neurology 1972; 22: 516–9

    PubMed  CAS  Google Scholar 

  31. Stern Y, Marder K, Xi Tang M, et al. Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 1993; 43: 1690–2

    PubMed  CAS  Google Scholar 

  32. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson’s disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988; 51: 529–33

    PubMed  CAS  Google Scholar 

  33. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long term drug therapy. Am J Psychiatry 1982; 139: 494–7

    PubMed  CAS  Google Scholar 

  34. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12(4): 483–96

    PubMed  CAS  Google Scholar 

  35. Factor SA, Molho ES, Podskalny GD, et al. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115–38

    PubMed  CAS  Google Scholar 

  36. Mayeux R. Parkinson’s disease: a review of cognitive and psychiatric disorders. Neuropsychiat Neuropsych Behav Neurol 1990; 3: 3–14

    Google Scholar 

  37. Factor SA, McAlarney T, Sanches-Ramos JR, et al. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord 1990; 5: 280–5

    PubMed  CAS  Google Scholar 

  38. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson’s disease: a retrospective analysis of a large multi-centered clinical experience. Mov Disord 1998; 13: 377–82

    PubMed  CAS  Google Scholar 

  39. Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson’s disease: treatment with clozapine. Mov Disord 1993; 8(2): 171–4

    PubMed  CAS  Google Scholar 

  40. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in 6 patients with parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556–9

    PubMed  CAS  Google Scholar 

  41. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 1995; 56: 556–9

    Google Scholar 

  42. Parsa MA, Simon M, Dubrow C, et al. Psychiatric manifestations of olivo-ponto-cerebellar atrophy treated with clozapine. Int J Psychiatr Med 1993; 23: 149–56

    CAS  Google Scholar 

  43. Findley LF. Tremors: differential diagnosis and pharmacology. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. 2nd ed. Baltimore: Williams and Wilkins, 1988: 293–314

    Google Scholar 

  44. Boshes B. Further insights into parkinsonian tremor. In: Birkmeyer W, Hornykiewicz O, editors. Advances in Parkinsonism. Basel: Roche, 1976

    Google Scholar 

  45. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986; 73: 295–7

    PubMed  CAS  Google Scholar 

  46. Fisher PA, Bass H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neurol Transm 1990; 2: 233–8

    Google Scholar 

  47. Friedman JH, Koller WC, Goldstein S, et al. BCLOZ: a double-blind, crossover trial comparing clozapine with benztropine for treatment of tremor in Parkinson’s disease [abstract]. Neurology 1996; 46 Suppl. : A476

    Google Scholar 

  48. Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology 1997; 48: 1077–81

    PubMed  CAS  Google Scholar 

  49. Korsgaard CH, Reeur L. Werdelin L. Clozapine in the treatment of tremor: clinical experience since 1986 [abstract]. Mov Disord 1994; 9 Suppl. : 20

    Google Scholar 

  50. Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson’s disease tremor: effects of acute and chronic administration. eurology 1997; 49(6): 1587–90

    CAS  Google Scholar 

  51. Arevalo GJG, Gershanik OS. Modulatory effect of clozapine on levodopa response in Parkinson’s disease: a preliminary tudy. Mov Disord 1993; 8(3): 349–54

    PubMed  CAS  Google Scholar 

  52. Auzou O, Ozsancak C, Hannequin D, et al. Clozapine for the treatment of psychosis in Parkinson’s disease: a review. Acta Neurol Scand 1996; 94: 329–36

    PubMed  CAS  Google Scholar 

  53. Linazasoro G, Suarez JA, Marti Masso JF. Clozapine in Parkinson’s disease: three years experience. Mov Disord 1992; 7 Suppl. : 100

    Google Scholar 

  54. Roberts HE, Dean RC, Stoudemire A. Clozapine treatment of psychosis in Parkinson’s disease. J Neuropsychiatr Clin Neurosci 1989; 1: 190–2

    CAS  Google Scholar 

  55. Gonski PN. The use of clozapine in Parkinson’s disease. Aust NZ J Med 1994; 24: 585

    CAS  Google Scholar 

  56. Ostergaard K, Dupont E. Clozapine treatment of drug-inducedpsychotic symptoms in late stages of Parkinson’s disease [letter]. Acta Neurol Scand 1988; 78: 349–50

    PubMed  CAS  Google Scholar 

  57. Gershanik O, Garcia S, Papa S et al. Analysis of the mechanism of action of clozapine in Parkinson’s disease [abstract]. Mov Disord 1992: 7 Suppl. 1: 101

    Google Scholar 

  58. Rabey JM, Treves TA, Neufeld MY, et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease. Neurology 1995; 45: 432–4

    PubMed  CAS  Google Scholar 

  59. Rui Silva M, Magalhaes M, Viseu M, et al. Clozapine in the treatment of psychosis in parkinsonism [abstract]. J Neurol 1995; 242 Suppl. 2: 138

    Google Scholar 

  60. Factor S A, Brown D. Clozapine prevents recurrence of psychosis in Parkinson’s disease. Mov Disord 1992; 7(2): 125–31

    PubMed  CAS  Google Scholar 

  61. Bennett JP Jr, Landow ER, Dietrich S, et al. Suppression of dyskinesia in advanced Parkinson’s disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994; 9(4): 409–14

    PubMed  Google Scholar 

  62. Bennett JP Jr, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson’s disease II: increasing daily clozapine doses suppress dyskinesias and improve motor symptoms. Neurology 1993; 43: 1551–5

    PubMed  Google Scholar 

  63. Meco G, Fabrizio E, Alessandri A, et al. Risperidone in levodopa-induced dyskinesia [letter]. J Neurol Neurosurg Psychiatry 1998; 64: 135–42

    PubMed  CAS  Google Scholar 

  64. Louis ED, Marder K, Cote L, et al. Prevalence of a history of shaking in persons 65 years of age or older: diagnostic and functional correlates. Mov Disord 1996; 11: 63–9

    PubMed  CAS  Google Scholar 

  65. Cerevolo R, Salvetti S, Dell’Agnello G, et al. Pharmacologic tools in the study of essential tremor [abstract]. Mov Disord 1996; 11 Suppl. 1: 255

    Google Scholar 

  66. Bonuccelli U, Ceravolo R, Maremmani C, et al. Clozapine in Huntington’s disease. Neurology 1994; 44: 822–3

    Google Scholar 

  67. Sajatovic M, Verbanac P, Ramirez LF, et al. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington’s chorea [case report]. Neurology 1991; 41: 156

    PubMed  CAS  Google Scholar 

  68. Colosimo C, Cassetta E, Bentvoglio AR, et al. Clozapine inHuntington’s disease [letter]. Neurology 1995; 45: 1023

    PubMed  CAS  Google Scholar 

  69. Van Vugt JPP, Siesling S, Vergeer M, et al. Clozapine versusplacebo in Huntington’s disease [abstract]. Mov Disord 1996; 11 Suppl. 1: 54

    Google Scholar 

  70. Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia [letter]. Lancet 1996; 347: 127–8

    PubMed  CAS  Google Scholar 

  71. Thiel A, Dressler D, Kistel C, et al. Clozapine treatment of spasmodic torticollis. Neurology 1994; 44: 957–872.

    PubMed  CAS  Google Scholar 

  72. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34(9): 1147–52

    PubMed  CAS  Google Scholar 

  73. Bruun RD, Budman CL. Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry 1996; 57(1): 29–31

    PubMed  CAS  Google Scholar 

  74. Caine ED, Jolinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorder. Am J Psychiatry 1979; 136: 317–20

    PubMed  CAS  Google Scholar 

  75. Khot V, Egan MF, Hyde TM, et al. Neuroleptics and classicaltardive dyskinesia. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt. Kisco (NY): Futura, 1992: 121–6

    Google Scholar 

  76. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58(7): 318–22

    PubMed  CAS  Google Scholar 

  77. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 1985; 235(1): 60–4

    CAS  Google Scholar 

  78. Wolters EC, Hurwitz RE, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40: 832–4

    PubMed  CAS  Google Scholar 

  79. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in idiopathic Parkinson’s disease. New Engl J Med 1999: 340: 757–63

    Google Scholar 

  80. Friedman JH, Max J, Swift R. Idiopathic Parkinson’s disease in chronic schizophrenic patient: long term treatment with clozapine and L-dopa. Clin Neuropharmacol 1987; 10: 470–5

    PubMed  CAS  Google Scholar 

  81. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 1989; 39: 1219–21

    PubMed  CAS  Google Scholar 

  82. Bear D, Lawson W, Burns S, et al. Clozapine in idiopathic Parkinson’s. Biol Psychiatry 1989; 25: 160A–165A

    Google Scholar 

  83. Pfeiffer RF, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson’s disease. Mov Disord 1990; 5: 239–42

    PubMed  CAS  Google Scholar 

  84. Bernardi F, Del Zompo M. Clozapine in idiopathic PD [letter]. Neurology 1990; 40(7): 1151–2

    PubMed  CAS  Google Scholar 

  85. Kahn N, Freeman A, Juncos JL, et al. Clozapine for psychosis in Parkinson’s disease. Mov Disord 1992; 41: 1699–700

    Google Scholar 

  86. Friedman JH, Lannon MC, Caley C. Clozapine for movement disorder patients: a retrospective analysis of 38 patients [abstract]. Ann Neurol 1992; 32: 277

    Google Scholar 

  87. Rosenthal SH, Fenton ML, Harnett DS. Clozapine for the treatment of levodopa-induced psychosis in Parkinson’s disease. Gen Hosp Psychiatry 1992; 14: 285–6

    PubMed  CAS  Google Scholar 

  88. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson’s disease: a report of 5 consecutive cases. J Clin Psychiatry 1992; 53: 373–6

    PubMed  CAS  Google Scholar 

  89. Green P, Cole L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurol 1993; 60: 703–6

    Google Scholar 

  90. Pinter MM, Helscher RJ. Therapeutic effect of clozapine inpsychotic decompensation in idiopathic Parkinson’s disease. J Neurol Transm Park Dis Demet Sect 1993; 5: 135–46

    CAS  Google Scholar 

  91. Lew MF, Water CF. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1993; 41: 669–71

    PubMed  CAS  Google Scholar 

  92. Koller WC, Pahwa R, Lyons K, et al. Low dose clozapine in the treatment of levodopa-induced psychosis [abstract]. Mov Disord 1994; Suppl. 1: 64

    Google Scholar 

  93. Factor SA, Brown D, Molho ES, et al. Clozapine: a two-year open trial in Parkinson’s disease patients with psychosis. Neurology 1994; 44: 544–6

    PubMed  CAS  Google Scholar 

  94. Auzou P, Hannequin D, Landrin I, et al. Worsening of psychotic symptoms by clozapine in Parkinson’s disease [case report]. Lancet 1994; 344: 955

    PubMed  CAS  Google Scholar 

  95. Brewer MA, Kurth MC, Imke SC, et al. Safety and effectiveness of clozapine for parkinsonian patients with psychosis [abstract]. Neurology 1995; 45 Suppl. 4: A252

    Google Scholar 

  96. Chacko RC, Hurley RA, Harper RG, et al. Clozapine for acute and maintenance treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1995; 7: 471–5

    PubMed  CAS  Google Scholar 

  97. Greene P. Clozapine therapeutic plunge in a patient with Parkinson’s disease. Lancet 1995; 45: 1172–3

    Google Scholar 

  98. Diedrich N, Keipes M, Graas M, et al. Clozapine in the treatment of mental manifestation of Parkinson’s disease. Rev Neurol (Paris) 1995; 151: 252–7

    Google Scholar 

  99. Meltzer HY. The role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995; 3: 64–75

    PubMed  CAS  Google Scholar 

  100. Wagner ML, Defilippi JL, Menza A, et al. Clozapine for the treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996; 8: 276–80

    PubMed  CAS  Google Scholar 

  101. Ruggieri S, De Pandis MF, Bonamartini A, et al. Low dose clozapine for the treatment of dopaminergic psychosis in Parkinson’s disease. Clin Neuropharmacol 1997; 20: 204–9

    PubMed  CAS  Google Scholar 

  102. Alvir JMA, Lieberman JA, Safferman AZ. Clozapine induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329(3): 162–7

    CAS  Google Scholar 

  103. Honigfeld G. Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with clozapine national registry. J Clin Psychiatry 1998; 59 Suppl. 3: 3–7

    Google Scholar 

  104. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson’s disease. Mov Disord 1990; 5: 225–9

    PubMed  CAS  Google Scholar 

  105. Kane JM, Honigfeld G, Singer J. Clozapine for the treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    PubMed  CAS  Google Scholar 

  106. Beasley CM, Sanger W, Satterlee G, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol (Berl) 1996; 124: 159–67

    CAS  Google Scholar 

  107. Kim E, Zivil AS, McAllister TW, et al. Treatment of organic bipolar mood disorders in parkinson’s disease [abstract]. Neurology 1996; 46: A375–6

    Google Scholar 

  108. Fernandez HH, Durso R. Clozapine for dopaminergic-induced paraphilias in Parkinson’s disease. Mov Disord 1998; 13(3): 597–8

    PubMed  CAS  Google Scholar 

  109. Juncos JL. Clozapine treatment of parkinsonian pain syndromes [abstract]. Mov Disord 1996; 11: 603–4

    Google Scholar 

  110. Jansen ENH. Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand 1994; 89: 262–5

    PubMed  CAS  Google Scholar 

  111. Trosch RM, Friedman JH, Lewitt PA. Clozapine treatment of dystonia in Parkinson’s disease [abstract]. Mov Disord 1994; 9 Suppl. 1: 102

    Google Scholar 

  112. Lang AE. Dopaminergic agonists and antagonists in the treatment of idiopathic dystonia. In: Fahn S, Marsden CD, Calne DB, editors. Dystonia 2. Advanced neurology. Vol. 50. New York: Raven Press, 1988: 561–70

    Google Scholar 

  113. Bashir K. Manyam BV. Clozapine for the control of hemiballismus. Clin Neuropharmacol 1994; 17: 477–80

    PubMed  CAS  Google Scholar 

  114. Labbate LA, Lande RG, Jones F, et al. Tardive dyskinesia in older out-patients: a follow up study. Acta Psychiatr Scand 1997; 96: 195–8

    PubMed  CAS  Google Scholar 

  115. Gardos G, Cole JO, Haskell D, et al. The natural history of tardive dyskinesia. J Clin Psychopharmacol 1988; 8: 31S–37S

    PubMed  CAS  Google Scholar 

  116. Fernandez HH, Krupp B, Friedman JH. The natural history of tardive dyskinesia in psychiatric in-patients [abstract]. The 51st Annual Meeting of the American Academy of Neurology; 1999 Apr 17–24; Toronto

  117. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994; 35(11): 886–7

    PubMed  CAS  Google Scholar 

  118. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54: 327–30

    PubMed  CAS  Google Scholar 

  119. Casey DE. Clozapine: neuroloeptic induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47–53

    PubMed  Google Scholar 

  120. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10

    PubMed  CAS  Google Scholar 

  121. Metzer HY, Luchins DL. Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 1984; 4: 286–7

    Google Scholar 

  122. Gerbino L, Shopsin B, Collra M. Clozapine in the treatment of tardive dyskinesias: an interim report. In: Fahn WE, Smith RC, Davis JM, editors. Tardive dyskinesias, research and treatment. New York: SP Medical and Scientific Books, 1980: 475–89

    Google Scholar 

  123. Cole JO, Gardos G, Tarsy D, et al. Drug trials in persistent dyskinesia. In: Fahn WE, Smith RC, Davis JM, editors. Tardive dyskinesia, research and treatment. New York: SP Medical and Scientific Books, 1980: 419–27

    Google Scholar 

  124. Gerlach J, Koppelhus P, Helwez E. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 1974; 50: 410–24

    PubMed  CAS  Google Scholar 

  125. Van Putten T, Wirshing WS, Marder SR. Tardive Meige syndrome responsive to clozapine. J Clin Psychopharmacol 1990; 10: 381–2

    PubMed  Google Scholar 

  126. Trugman JM, Leadbetter R, Zalis ME, et al. Treatment of severe axial tardive dystonia with clozapine: case report and hypotheses. Mov Disord 1994; 9: 441–6

    PubMed  CAS  Google Scholar 

  127. Friedman JH. Clozapine treatment in psychosis in patients with tardive dystonia: report of 3 cases. Mov Disord 1994; 9: 321–4

    PubMed  CAS  Google Scholar 

  128. Bonuccelli U, Abbruzzese G, Gerarolo R, et al. Successful treatment with clozapine in 4 patients with tardive dystonia [abstract]. Mov Disord 1996; 11 Suppl. 1: 220

    Google Scholar 

  129. Valevski A, Radvan M, Hermesh H, et al. Successful treatment of severe generalized dystonia with clozapine [abstract]. Mov Disord 1996; 11 Suppl. 1: 230

    Google Scholar 

  130. Borg M, Chatel M. Treatment of axial tardive dystonia with clozapine [abstract]. Mov Disord 1996; 11 Suppl. 1: 212

    Google Scholar 

  131. Jaffe E, Tremeau F, Sharif Z, et al. Clozapine in tardive Tourette syndrome. Biol Psychiatry 1995; 38: 196–7

    PubMed  CAS  Google Scholar 

  132. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994; 55 Suppl. B: 107–9

    PubMed  Google Scholar 

  133. Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Ment Health Serv 1993; 31: 14–8

    CAS  Google Scholar 

  134. Simpson G, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesias. Psychopharmacology 1978; 56: 75–80

    PubMed  CAS  Google Scholar 

  135. Small JG, Milstein V, Markenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment resistant psychosis. J Clin Psychiatry 1987; 48: 263–7

    PubMed  CAS  Google Scholar 

  136. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55 (9 Suppl. B): 102–6

    PubMed  Google Scholar 

  137. Wilson WH. Clinical review of clozapine treatment in a state psychiatric hospital. Hosp Community Psychiatry 1992; 43: 700–3

    PubMed  CAS  Google Scholar 

  138. Simpson GM, Amuso D, Blair JH, et al. Phenothiazine-produced extrapyramidal disturbance. Arch Gen Psychiatry 1964; 10: 127–37

    Google Scholar 

  139. Grant S. Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253–73

    CAS  Google Scholar 

  140. Cohen L. Risperidone. Pharmacotherapy 1994; 14: 253–73

    PubMed  CAS  Google Scholar 

  141. Cardoni A. Risperidone: review and assessment of its role in thetreatment of schizophrenia. Ann Pharmacother 1995; 29: 610–8

    PubMed  CAS  Google Scholar 

  142. Livingston MG. Risperidone. Lancet 1994; 343: 457–60

    PubMed  CAS  Google Scholar 

  143. Bunney BS. Clozapine: a hypothesized mechanism for its unique clinical profile. Br J Psychiatry 1992; 160 Suppl. 17: 17–21

    Google Scholar 

  144. Rosebush PI, Mazurek MF. Extrapyramidal side effects of risperidone [abstract]. Neurology 1997; 48: A325

    Google Scholar 

  145. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59(2): 69–75

    PubMed  CAS  Google Scholar 

  146. Friedman JH. Risperidone induced tardive dyskinesia (‘fly catcher tongue’) in a neuroleptic naïve patient. Med Health RI 1998; 81(8): 271–2

    CAS  Google Scholar 

  147. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson’s disease patients [letter]. Lancet 1994; 343: 1370–1

    PubMed  CAS  Google Scholar 

  148. Workman RH, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuro Psychiatry 1997; 9(4): 594–7

    CAS  Google Scholar 

  149. Koponen HJ. Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly [letter]. Int J Geriatr Psychiatry 1997; 12(3): 412–3

    PubMed  CAS  Google Scholar 

  150. Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease [letter]. Lancet 1994; 344: 681

    PubMed  CAS  Google Scholar 

  151. DeLeon OA, Jobe TH, Furmaga KM, et al. Severe extrapyramidal reaction due to risperidone in a case of neurofibromatosis [letter]. J Clin Psychiatry 1997; 58(7): 323

    CAS  Google Scholar 

  152. Chapel JL, Brown N, Jenkins RL. Tourette’s disease: symptomatic relief with haloperidol. Am J Psychiatry 1964; 121: 608–10

    PubMed  CAS  Google Scholar 

  153. Lucas AR, Kauffman PE, Morris EM. Gilles de la Tourette’s disease: a clinical study of 15 cases. J Am Acad Child Psychiatry 1967; 6: 700–22

    PubMed  CAS  Google Scholar 

  154. Shapiro AK, Shapiro E. Treatment of Gilles de la Tourette syndrome with haloperidol. Br J Psychiatry 1968; 114: 345–50

    PubMed  CAS  Google Scholar 

  155. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette syndrome. Am J Psychiatry 1978; 135: 585–7

    PubMed  CAS  Google Scholar 

  156. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette syndrome with pimozide. Am J Psychiatry 1983; 140: 1183–6

    PubMed  CAS  Google Scholar 

  157. Shapiro AK, Shapiro E. Controlled study of pimozide vs placebo in Tourette’s syndrome. J Am Acad Child Psychiatry 1984; 23: 161–73

    PubMed  CAS  Google Scholar 

  158. Kopala LC, Honer WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol 1994; 14: 430–1

    PubMed  CAS  Google Scholar 

  159. Rangwani SR, Gupta S, Burke WJ, et al. Improvement of debilitating tardive dyskinesia with risperidone. Ann Clin Psychiatry 1996; 8(1): 27–9

    PubMed  CAS  Google Scholar 

  160. Barnes TRE, Liddle PF, Curson DA, et al. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia. Br J Psychiatry 1989; Suppl. 7: 99–103

    Google Scholar 

  161. Simpson GM, Lidenmayer J. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17: 194–201

    PubMed  CAS  Google Scholar 

  162. Woerner MG, Sheitman BB, Lieberman JA, et al. Tardive dyskinesia induced by risperidone? [letter]. Am J Psychiatry 1996; 153(6): 843

    PubMed  CAS  Google Scholar 

  163. Addington DE, Toews JA, Addington JM. Risperidone and Tardive dyskinesia: a case report [letter]. J Clin Psychiatry 1995; 56(10): 484

    PubMed  CAS  Google Scholar 

  164. Feeney DJ, Klykylo W. Risperidone and tardive dyskinesia [letter]. J Am Acad Child Adolesc Psychiatry 1996; 35: 1421–42

    PubMed  CAS  Google Scholar 

  165. Saran BM. Risperidone-induced tardive dyskinesia [letter]. J Clin Psychiatry 1998; 59(1): 29–30

    PubMed  CAS  Google Scholar 

  166. Buzan RD. Risperidone-induced tardive dyskinesia [letter]. Am J Psychiatry 153 (5): 734–5

  167. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine: a novel ‘atypical’ antipsychotic agent. J Pharmacol Exp Ther 1992; 262: 545–51

    PubMed  CAS  Google Scholar 

  168. Seeman P, Van Tol HM. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6: 602–8

    PubMed  CAS  Google Scholar 

  169. Bymaster FD, Colligaro DO, Falcone JF, et al. Radio receptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87–96

    PubMed  CAS  Google Scholar 

  170. Fuller RW, Snoddy D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine and antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992; 77: 87–93

    PubMed  CAS  Google Scholar 

  171. Beasley CM Jr, Tollefson GD, Tran PD. Efficacy of olanzapine: an overview of pivotal trials. J Clin Psychiatry 1997; 58 Suppl. 10: 7–12

    PubMed  CAS  Google Scholar 

  172. Wolters EC, Jansen ENH, Tuyma-Qua HG, et al. Olanzapine in the treatment of dopaminomimentic psychosis in patients with arkinson’s disease. Neurology. 1996; 47: 1085–7

    PubMed  CAS  Google Scholar 

  173. Jimenez-Jimenez FJ, Tallo-Barranco A, Orti-Pareja M, et al. Olanzapine can worsen parkinsonism. Neurology 1998; 50: 1183–4

    PubMed  CAS  Google Scholar 

  174. Friedman JH, Goldstein SM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s Disease. Neurology 1998; 50: 1195–6

    PubMed  CAS  Google Scholar 

  175. Friedman JH, Goldstein SM, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson’s disease patients: results of an open-label pilot trial. Clin Neuropharmacol 1998; 21(5): 285–8

    PubMed  CAS  Google Scholar 

  176. Molho ES, Factor SA. Worsening of motor features of Parkinson’s disease with olanzapine [abstract]. Mov Disord 1998; 13 Suppl. 2: 256

    Google Scholar 

  177. O’Brien J, Barber R. Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject [letter]. Br J Psychiatry 1998; 172: 186–9

    PubMed  Google Scholar 

  178. Littrell KH, Johnson CG, Littrell S, et al. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 1998; 55: 279–80

    PubMed  CAS  Google Scholar 

  179. Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154: 1248–54

    PubMed  CAS  Google Scholar 

  180. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus haloperidol: acute phase results of the North America double-blind olanzapine trial. Neuropsychopharmacology 1996; 111–23

    Google Scholar 

  181. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychophamacol 1997; 7: 125–37

    CAS  Google Scholar 

  182. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65

    PubMed  CAS  Google Scholar 

  183. Carey G, Bergamn J. Discriminative stimulus effects of proposed atypical antipsychotics in clozapine trained squirrels and monkeys. Behav Pharmacol 1994; 5 Suppl. 1: 114

    Google Scholar 

  184. Small JG, Hirsch SR, Arvantis LA, et al. Quetiapine in patients with schizophrenia. A high and low-dose double blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549–57

    CAS  Google Scholar 

  185. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of ‘seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46

    PubMed  CAS  Google Scholar 

  186. Evatt ML, Jewart D, Juncos JL. ‘Seroquel’ treatment of psychosis in parkinsonism [abstract]. Mov Disord 1996; 11(5): 595

    Google Scholar 

  187. Juncos JL, Evatt ML, Jewart D. Long term effect of quetiapine fumarate in parkinsonism complicated by psychosis [abstract]. Neurology 1998; 50 Suppl. 4: A70–71

    Google Scholar 

  188. Samantha J, Stacy M. Quetiapine in the treatment of hallucinations in advanced Parkinson’s disease [abstract]. Mov Disord 1998; 13 Suppl. 2: 274

    Google Scholar 

  189. Parsa M, Basteni B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson’s disease. Neuropsychiatry 1998; 10: 1–4

    Google Scholar 

  190. Fernandez HH, Friedman JH, Jacques CJ, et al. Quetiapine for drug-induced psychosis in Parkinson’s disease. Mov Disord. In press

Download references

Author information

Authors and Affiliations

  1. Movement Disorders Unit, Department of Neurology, Brown University School of Medicine, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, USA

    Hubert H. Fernandez & Joseph H. Friedman

Authors
  1. Hubert H. Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph H. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert H. Fernandez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernandez, H.H., Friedman, J.H. The Role of Atypical Antipsychotics in the Treatment of Movement Disorders. Mol Diag Ther 11, 467–483 (1999). https://doi.org/10.2165/00023210-199911060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199911060-00005

Keywords

Search

Navigation